A recent article published in the journal Deutsches Ärzteblatt International details the pathophysiology, diagnosis, and treatment of Moyamoya disease (MMD), a rare cerebrovascular angiopathy. Whereas historically associated with Japan and East Asia, diagnoses are increasingly occurring outside of these regions.
Moyamoya disease is characterized by the stenosis of the intracranial internal carotid arteries and the subsequent development of collateral vessels. The condition can lead to both ischemic and hemorrhagic stroke in both children and adults, accounting for approximately 6–10% of strokes and transient ischemic attacks in childhood, according to the review.
Researchers have identified a multifactorial pathogenesis involving genetic predisposition – particularly mutations in the RNF213 gene – and vascular remodeling processes, with endothelial dysfunction playing a key role. A study published in March 2024 in J Neurol examined cases in Southeast Asians, noting an association with a specific genetic marker, p.4810 K, in East Asian populations like Japan and Korea.
Diagnosis relies on modern imaging techniques, including digital subtraction angiography (DSA), magnetic resonance imaging (MRI), and positron emission tomography (PET), alongside evolving classification systems. The review highlights surgical revascularization, specifically combined bypass surgery, as the most effective therapeutic approach currently available.
Data from a specialized center treating over 500 Moyamoya patients indicates a low complication rate of 6.3% following combined bypass surgery, alongside a low postoperative stroke rate. A separate article published just hours ago by Taylor & Francis confirms the increasing recognition of the disease beyond its traditional geographic boundaries.
The incidence of Moyamoya disease in East Asian countries such as Japan, Korea, and China is approximately 1 per 100,000 population, according to the Deutsches Ärzteblatt International review.
